Left Atrial Appendage Closure after Ablation for Atrial Fibrillation

• Published in: The New England journal of medicine
• Main Authors: Wazni, Oussama M, Saliba, Walid I, Nair, Devi G, Marijon, Eloi, Schmidt, Boris, Hounshell, Troy, Ebelt, Henning, Skurk, Carsten, Oza, Saumil, Patel, Chinmay, Kanagasundram, Arvindh, Sadhu, Ashish, Sundaram, Sri, Osorio, Jose, Mark, George, Gupta, Madhukar, DeLurgio, David B, Olson, Jeffrey, Nielsen-Kudsk, Jens Erik, Boersma, Lucas V A, Healey, Jeff S, Phillips, Karen P, Asch, Federico M, Wolski, Katherine, Roy, Kristine, Christen, Thomas, Sutton, Brad S, Stein, Kenneth M, Reddy, Vivek Y
• Format: Journal Article
• Language: English
• Published: United States 16.11.2024
• ISSN: 1533-4406
• DOI: 10.1056/NEJMoa2408308

Oral anticoagulation is recommended after ablation for atrial fibrillation among patients at high risk for stroke. Left atrial appendage closure is a mechanical alternative to anticoagulation, but data regarding its use after atrial fibrillation ablation are lacking. We conducted an international randomized trial involving 1600 patients with atrial fibrillation who had an elevated score (≥2 in men and ≥3 in women) on the CHA DS -VASc scale (range, 0 to 9, with higher scores indicating a greater risk of stroke) and who underwent catheter ablation. Patients were randomly assigned in a 1:1 ratio to undergo left atrial appendage closure or receive oral anticoagulation. The primary safety end point, tested for superiority, was non-procedure-related major bleeding or clinically relevant nonmajor bleeding. The primary efficacy end point, tested for noninferiority, was a composite of death from any cause, stroke, or systemic embolism at 36 months. The secondary end point, tested for noninferiority, was major bleeding, including procedure-related bleeding, through 36 months. A total of 803 patients were assigned to undergo left atrial appendage closure, and 797 to receive anticoagulant therapy. The mean (±SD) age of the patients was 69.6±7.7 years, 34.1% of the patients were women, and the mean CHA DS -VASc score was 3.5±1.3. At 36 months, a primary safety end-point event had occurred in 65 patients (8.5%) in the left atrial appendage closure group (device group) and in 137 patients (18.1%) in the anticoagulation group (P<0.001 for superiority); a primary efficacy end-point event had occurred in 41 patients (5.3%) and 44 patients (5.8%), respectively (P<0.001 for noninferiority); and a secondary end-point event had occurred in 3.9% and 5.0% (P<0.001 for noninferiority). Complications related to the appendage closure device or procedure occurred in 23 patients. Among patients who underwent catheter-based atrial fibrillation ablation, left atrial appendage closure was associated with a lower risk of non-procedure-related major or clinically relevant nonmajor bleeding than oral anticoagulation and was noninferior to oral anticoagulation with respect to a composite of death from any cause, stroke, or systemic embolism at 36 months. (Funded by Boston Scientific; OPTION ClinicalTrials.gov number, NCT03795298.).